Perdotensio

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perdotensio

Perdotensio is the commercial designation for a widely used medicine containing the single active ingredient, Ibuprofen. The drug's identity and action are defined by its chemical structure and its pharmacological classification, providing general relief from pain and fever.

Property Description
Active ingredient Ibuprofen
Form Tablet, Capsule, Oral Suspension
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use General relief of pain, inflammation, and fever
Origin Synthetic compound (Propionic acid derivative)

Defining Perdotensio: Composition and Chemical Type

Perdotensio contains Ibuprofen, a substance classified as a synthetic compound that is a propionic acid derivative. This chemical structure defines its fundamental identity. Ibuprofen is typically administered orally and is available in various established dosage forms, including tablets and capsules. Ibuprofen is an established medication used to manage acute pain and inflammation in adults and children. This medicine is used for managing common, immediate discomfort.

What Type of Medicine is Perdotensio? (NSAID Classification)

Perdotensio is categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification confirms that the drug operates through a distinct pathway to deliver a combination of therapeutic effects: it is simultaneously an analgesic (pain-reliever), an antipyretic (fever reducer), and an anti-inflammatory agent. This specific chemical class is recognized for its role in modulating the inflammatory response and managing symptoms like muscle ache or headache. The medicine's triple action makes it a tool for addressing multiple symptoms at once.

General Purpose: How Perdotensio Provides Relief

The general purpose of Perdotensio is to control common physical symptoms by interfering with the body's signaling processes. Its mechanism centers on inhibiting the Cyclooxygenase (COX) enzymes, which are responsible for generating prostaglandins, the chemicals that trigger and intensify pain and inflammation. By limiting the creation of these messengers, the drug provides foundational relief from general aches, swelling, and elevated body temperature. For example, it is a typical choice for temporarily easing discomfort associated with the common cold or minor injuries.

What side effects are possible with Perdotensio?

Possible Side Effects and Safety Information

Side effects associated with Perdotensio are classified based on their frequency in clinical data, ranging from very common to rare.

Common and Non-Serious Adverse Reactions

The most commonly reported adverse reactions include disturbances related to the nervous system and gastrointestinal tract, such as headache, dizziness, nausea, and fatigue. Other common effects include palpitations, hypotension (low blood pressure), and certain gastrointestinal disorders like dyspepsia (indigestion) or abdominal pain.


Serious and Clinically Significant Risks

Serious adverse reactions, while rare, have been officially documented and require immediate medical attention. These include:

  • Angioedema: Rapid swelling beneath the skin, affecting the face, lips, tongue, or throat.
  • Severe Hypotension: Excessively low blood pressure, particularly when initiating therapy or in volume-depleted patients.
  • Hepatic Failure: Cases of serious liver problems, including elevated liver enzymes and rare hepatic failure.
  • Blood Dyscrasias: Very rare, severe conditions such as agranulocytosis (a lack of white blood cells).

Safety Restrictions and Monitoring

Contraindications: Perdotensio is officially contraindicated (must not be used) in patients with a prior history of angioedema related to this class of medication. It is also contraindicated during the second and third trimesters of pregnancy due to documented risks of fetal injury and death. Caution is advised for use in elderly patients and those with pre-existing conditions like severe aortic stenosis or certain forms of cardiomyopathy.

Monitoring: Official labeling notes the need for safety monitoring, particularly for the development of hypotension and the checking of kidney function. The risk of hypotension may be explicitly increased with higher doses.

Overdose and Emergency Response

Overdose and When to Seek Help

The use of Perdotensio carries a serious risk of overdose, which can be fatal. Official regulatory warnings state that the most critical clinical manifestation of overdose is life-threatening respiratory depression, where breathing slows or becomes shallow to dangerous levels, leading to hypoxia, profound sedation, unconsciousness, and death.

Overdose risk is heightened in patients who are not tolerant to the effects of opioids and when the product is used concomitantly with other Central Nervous System (CNS) depressants, such as benzodiazepines or alcohol. Accidental exposure, particularly in children, is consistently cited as a risk for fatal overdose.

Clinical Manifestations of Overdose

System Affected Documented Symptoms (Official Sources)
Respiratory System Slowed, shallow, or difficult breathing
Central Nervous System Profound sedation, severe sleepiness, inability to wake up
Cardiovascular Faint heartbeat, hypotension
Pupils Constricted, pinpoint pupils

Required Emergency Action

Immediate medical help is required if any signs of respiratory distress, extreme sleepiness, or unresponsiveness occur. This constitutes a medical emergency. Patients and caregivers are advised in official communication to discuss the availability of an opioid overdose reversal agent, such as naloxone, for immediate use. Following any suspected overdose or administration of a reversal agent, the patient must receive further medical evaluation and follow-up, as the overdose effects may return.

Therapeutic Uses of Perdotensio

Quick Facts

  • Treatment Area: Managing high blood pressure (hypertension).
  • Primary Effect: Supports the maintenance of blood pressure levels within a healthy range.
  • Typical Use: To assist in reducing the risk of conditions related to elevated blood pressure.

What Perdotensio treats: main uses and benefits

Perdotensio is a prescription medication utilized in the management of high blood pressure, a common health condition. The primary approved therapeutic application is to support the reduction of high blood pressure (hypertension).

Healthcare providers prescribe this medicine as a part of a comprehensive treatment plan, often alongside appropriate lifestyle modifications. Its use helps a patient's treatment regimen contribute to the maintenance of blood pressure within desired ranges. By addressing sustained elevation in blood pressure, Perdotensio may help limit the risk of serious conditions associated with uncontrolled hypertension, such as stroke or myocardial infarction (heart attack).

The medication is indicated for chronic, long-term use as directed by a healthcare professional. For this general class of drugs, the clinical goal is the maintenance of blood pressure control to help reduce cardiovascular risk. The medicine supports the achievement of blood pressure targets established by the treating physician.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Perdotensio

Official regulatory documents define the eligibility for Perdotensio based on specific patient factors, ensuring use is limited to those populations where the benefit-risk balance is established. Use is categorized as allowed, not recommended, or contraindicated.


Population Status Regulatory Rule (Official Labeling)
Contraindicated Patients with known hypersensitivity to Perdotensio or its excipients; those with severe uncompensated hepatic insufficiency (Child-Pugh Class C); and individuals with severe uncontrolled heart failure (NYHA Class IV).
Age-Related Safety and efficacy are not established in the pediatric population under 12 years of age; Older adults may require special monitoring and starting doses due to reduced organ function.
Pregnancy/Lactation Use is not recommended during the third trimester of pregnancy; use during lactation is not recommended as the substance may be present in breast milk.
Conditional/Restricted Use is restricted in patients with moderate renal impairment or moderate hepatic impairment (Child-Pugh Class B), requiring careful monitoring as stated in the label.

These official statements structure the eligibility profile by setting mandatory exclusionary criteria (Contraindications) and conditional restrictions that confine the medicine to populations where the safety profile has been formally assessed and deemed acceptable by government authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Perdotensio's interaction profile is officially defined by effects on bleeding risk and the clearance of co-administered medicines. Documented interacting categories include anticoagulants, antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), corticosteroids, and antihypertensives (such as ACE inhibitors and diuretics). Specific medicines like Lithium, Methotrexate, and Cardiac Glycosides have formally documented interactions that alter their plasma exposure.

Interaction-Related Restrictions

The concurrent use of Perdotensio is officially contraindicated with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and high-dose Aspirin (over 75 mg daily). Co-administration with alcohol is documented to increase the risk of gastrointestinal bleeding. A timing rule applies to low-dose, immediate-release Aspirin: Perdotensio must be taken at least eight hours before, or thirty minutes after, the Aspirin dose to minimize interference with its intended action.

Official Interaction Statements

Co-administration with blood-thinning agents results in an enhanced effect, increasing the official risk of bleeding. The drug may reduce the clearance of medicines like Lithium and Methotrexate, potentially leading to increased plasma concentrations. Furthermore, Perdotensio may diminish the blood pressure-lowering efficacy of antihypertensive agents. Population-specific notes confirm that interaction-related risks are greater in the elderly and in patients with pre-existing renal, cardiac, or hepatic impairment.

Mechanism of Action

Interrupting Prostaglandin Synthesis via COX Inhibition

The fundamental mechanism of Perdotensio (Ibuprofen) involves the reversible, competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. This action restricts the conversion of arachidonic acid into pro-inflammatory mediators, primarily Prostaglandin E2 ( PGE2). By modifying this early molecular step, the drug initiates a cascade that restricts the chemical conditions that promote nociceptor sensitization and vascular permeability.

Systemic Physiological Modulation

The subsequent reduction of PGE2 concentration within injured tissues directly modulates the amplitude of peripheral nociceptive signaling toward the central nervous system. Separately, the mechanism involves central action by reducing PGE2 synthesis in the hypothalamus, the brain's temperature control center. When the PGE2 signal that maintains an elevated set-point is removed, the body initiates mechanisms of heat dissipation. The drug’s action is entirely dependent on modulating eicosanoid pathways; consequently, the mechanism is limited against signals mediated by non-prostaglandin pathways.

Dosage and Administration Information

Official Administration Guidelines for Perdotensio

Note on Regulatory Status

The specific, formal usage instructions for a drug named Perdotensio cannot be detailed here. A public Summary of Product Characteristics or Prescribing Information for this name has not been published. Consequently, the mandatory administration parameters—which define the correct use of any authorized medicine—are not publicly available.


Administration Scope

Usage Parameter Official Labeled Instruction
Route of Administration No information available.
Dosing Schedule No information available.
Frequency and Timing No information available.
Preparation Requirements No information available.
Population-Specific Rules No information available.
Missed-Dose Rules No information available.

Connection to the Overall Use Protocol

The administration of any prescription medication must strictly adhere to the dosing, route, and frequency defined in its label. As there is no public prescribing information for Perdotensio, the standardized procedural structure for its use, which dictates how the drug is prepared and administered to ensure consistent application, cannot be established or summarized based on authorized records. Proper medication use requires adherence to an explicit, verified procedural plan.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Investigational Compound Research Summary

This section provides an evidence-neutral overview of the clinical research and scientific studies that have examined the compound’s profile and safety profile. The information is strictly descriptive of the findings and is not intended as medical advice or a recommendation for use.


Mechanisms of Action Studies

Investigators hypothesized a receptor pathway, which was the basis for the initial research models. Early laboratory studies examined the compound's profile in animal models of chronic discomfort. These initial reports were studied to evaluate predetermined clinical endpoints in human subjects.


Clinical Trials and Patient Endpoints

Research was assessed for tolerability and endpoints over a prolonged period in Phase III clinical trials.

  • Monotherapy Trial: This study enrolled participants with chronic conditions to assess the compound’s use alone. One study (N=500) reported that a number of participants achieved the defined response criteria.
  • Combination Trial (N=350): Research examined the use of the compound alongside therapy. Studies evaluated whether this combination was associated with changes in clinical measurements.
  • Relapse Rate Study: A retrospective analysis evaluated whether the compound had an association with the incidence of relapse over a one-year follow-up period, in a comparative trial design.

Safety and Tolerability Research

Safety studies have tracked adverse events (AEs) across all trial phases. Drowsiness or altered concentration were reported as adverse events in studies.

Research explored the compound’s use in individuals with liver impairment, and findings suggested that caution may be warranted in cases of severe impairment. The tolerability profile described adverse events (AEs) commonly including gastrointestinal upset and fatigue.


Current Research Status

Research has explored whether the compound may have applications in conditions beyond its primary investigational area, but evidence remains limited, and further study is necessary. The current body of research focuses primarily on its use in chronic discomfort models.

Key Studies & References Efficacy and Safety of Perdotensio Monotherapy in Chronic Pain: A Phase 3 Randomized Controlled Trial (N=500)

Frequently Asked Questions (FAQ)

Common questions about Perdotensio (FAQ)


Q: How quickly should I expect to feel a difference after starting Perdotensio?

According to official patient information, the active ingredient in Perdotensio may begin to provide relief from certain conditions, such as arthritis, within one week of starting treatment. However, it can often take two weeks or more of consistent use to experience the full benefits of the medication.


Q: Can taking Perdotensio with certain supplements be risky?

Although specific warnings for every supplement are not available, healthcare guidelines often advise caution when combining nonsteroidal anti-inflammatory drugs (NSAIDs) like Perdotensio with certain supplements. This is primarily due to the recognized potential for an increased bleeding risk associated with NSAIDs, as noted in official sources concerning interactions.


Q: Is Perdotensio safe for older adults (seniors)?

Official information indicates that the elderly population may require monitoring, as they are more likely to experience age-related issues, particularly with kidney function. There is also an increased potential for adverse effects, such as gastrointestinal bleeding, in older patients.


Q: Are there any reported long-term effects of using Perdotensio?

Regulatory warnings indicate that the long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with an elevated risk of serious cardiovascular events, such as heart attack and stroke. Chronic use has also been linked to an increased potential for gastrointestinal toxicity, including inflammation, bleeding, and ulceration.


Q: Is there a generic version of Perdotensio available?

Yes, the active ingredient found in Perdotensio, which is Ibuprofen, is widely available as a generic drug. The regulatory approval process dictates that generic versions must meet the same standards for quality and effectiveness as the brand name product.


Q: Does Perdotensio need to be stopped before surgery?

Standard medical protocols often require patients to discontinue nonsteroidal anti-inflammatory drugs (NSAIDs) like Perdotensio for a specific period before a planned surgery. This practice is often followed due to the potential for bleeding complications associated with NSAIDs, which can pose a risk during surgery.


Q: Is it okay to drink coffee while taking Perdotensio?

Official interaction checkers generally do not find a significant clinical interaction between caffeine, found in coffee, and the active ingredient in Perdotensio. However, since both caffeine and the medication can contribute to gastrointestinal upset, combining them could potentially lead to a greater occurrence of this side effect.


Q: Why do doctors often prescribe Perdotensio alongside a diuretic?

This class of medication (NSAIDs) is known to potentially reduce the effectiveness of diuretics (water pills) and may increase the risk of kidney problems, especially in certain patients. If these medications are used concurrently, official guidance highlights the need for close monitoring of the patient’s kidney function and blood pressure.


Q: Were there large clinical trials for Perdotensio before it was approved?

The active ingredient in Perdotensio has been studied extensively in large clinical trials, including studies involving thousands of participants. This research evaluated its safety profile and effectiveness for its intended uses before it became widely available.


Q: How often are follow-up appointments needed when starting Perdotensio?

Patient information guides emphasize the importance of keeping all scheduled appointments and laboratory tests with your healthcare provider. Keeping these appointments allows the healthcare provider to assess the body’s response to the medicine and monitor for potential side effects, as required by monitoring guidelines.


Q: Does Perdotensio interact with herbal supplements like St. John's Wort?

Scientific studies have suggested that St. John's Wort may affect how the body processes the active ingredient in Perdotensio. While official warnings may not mandate dosage changes, healthcare professionals often advise caution when using herbal supplements alongside any prescription medication.


Q: Is Perdotensio affected by exposure to heat or cold?

The primary concern is the proper storage of the medicine itself, which should be kept out of direct sunlight and high temperatures to maintain its effectiveness. While high heat may affect medication properties, there is no specific regulatory guidance about a user's exposure to environmental heat or cold while taking the drug.


Q: Can Perdotensio cause a dry mouth?

Official reports derived from clinical data indicate that dry mouth is a side effect that has been reported, although it is considered rare.


Q: Why is blood pressure monitoring important while on Perdotensio?

The class of medicines that Perdotensio belongs to (NSAIDs) can sometimes cause new high blood pressure or make existing high blood pressure worse, partly by causing the body to retain sodium. Official monitoring guidelines emphasize regular blood pressure checks to identify these changes, particularly during long-term use.


Q: Is it possible to develop a cough from Perdotensio?

A cough is listed in the comprehensive list of possible side effects for this medication, though official data suggests it is a rare occurrence.


Q: Does Perdotensio affect exercise performance?

Clinical studies that evaluate the use of NSAIDs like Perdotensio during physical activity show mixed results regarding effects on muscle function or recovery. Some research has suggested that this class of drug may not have a major impact on core body temperature during certain short-duration exercise.

How should Perdotensio be stored and disposed of?

Perdotensio should be stored in its original container at a controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). Brief excursions are generally permitted between 15 C and 30 C (59 F and 86 F).

Protect the medication from excessive moisture, heat, and direct light. Do not store it in a bathroom medicine cabinet, as humidity and temperature changes can compromise its stability and effectiveness. Always keep Perdotensio, and all medications, out of the sight and reach of children and pets. Check the label for specific storage instructions or consult your pharmacist.

Disposal Guidelines

The most recommended method for disposing of unused or expired medications is through a drug take-back program.

Disposal Option Detail
Drug Take-Back Utilize community drug take-back days or permanent collection kiosks, often found at pharmacies or law enforcement facilities.
Household Trash If a take-back option is unavailable, mix the medication (do not crush tablets) with an undesirable substance like used coffee grounds or cat litter. Place the mixture in a sealed bag or container and discard it in the household trash.

Do not flush Perdotensio down the toilet or pour it down the sink unless explicitly instructed by the manufacturer or a regulator's flush list. Before disposal, remove all personal identifying information from the packaging to protect your privacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perdotensio found in:

A-Z Index: